Kamada (KMDA) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a buy rating in a report released on Friday morning. The brokerage currently has $6.25 price objective on the biotechnology company’s stock.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

Other equities research analysts also recently issued reports about the company. ValuEngine downgraded Kamada from a sell rating to a strong sell rating in a report on Friday, June 1st. HC Wainwright set a $11.00 price target on Kamada and gave the stock a buy rating in a report on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $7.81.

KMDA stock opened at $5.25 on Friday. The company has a market capitalization of $209.37 million, a PE ratio of 29.17 and a beta of 1.22. Kamada has a twelve month low of $3.75 and a twelve month high of $6.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.95 and a quick ratio of 2.44.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.05. The business had revenue of $33.84 million during the quarter, compared to the consensus estimate of $29.64 million. Kamada had a return on equity of 14.43% and a net margin of 11.79%. sell-side analysts predict that Kamada will post 0.22 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of KMDA. Acadian Asset Management LLC lifted its holdings in shares of Kamada by 157.8% during the second quarter. Acadian Asset Management LLC now owns 292,795 shares of the biotechnology company’s stock worth $1,507,000 after purchasing an additional 179,237 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Kamada by 14.8% during the second quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock worth $616,000 after purchasing an additional 15,440 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Kamada by 8.1% during the second quarter. Renaissance Technologies LLC now owns 464,900 shares of the biotechnology company’s stock worth $2,417,000 after purchasing an additional 34,800 shares during the period. 10.21% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).

Featured Story: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply